Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Anavex Reports Fiscal Third Quarter 2016 Financial Results
August 11, 2016 4:15 PM EDTNEW YORK, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimers disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and nine months ended June 30, 2016.
Highlights:
The SEC staff recently advised Companys legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection... More